Results

1–10 of 10 results for TKI

OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-Release Axitinib Implant (OTX-TKI) for NPDR
Dilsher S. Dhoot, MD
Annual Meeting Talks
2024
AI in Retina Practice
Nathan J. Rudometkin, MD
Updates from the Field
2025
Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Tumor of Retina
Janet Atkinson
Retina Image Bank: Images of the Week
Update on the Association of Intracameral Vancomycin and Hemorrhagic Occlusive Retinal Vasculitis
Andre J. Witkin, MD
Updates from the Field
2016